

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	15.5	58.2	(26.6-110.6)	Male	9	9.0	99.9	(45.6-189.6)
Female	4	5.8	nc	(nc-nc)	Female	9	7.6	119.2	(54.4-226.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	5	2.6	191.5	(61.7-446.9)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	8.2	158.5	(84.3-271.1)
Female	69	59.7	115.5	(89.9-146.2)	Female	5	7.5	66.6	(21.5-155.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	7	6.2	113.7	(45.5-234.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	23.4	64.2	(35.9-105.9)	Female	2	2.9	nc	(nc-nc)
Female	43	22.8	188.5	(136.4-253.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	6	4.0	149.4	(54.5-325.1)	Male	45	61.8	72.8	(53.1-97.5)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.3	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.7	103.9	(41.6-214.2)	Female	13	12.3	105.7	(56.2-180.7)
Female	5	4.2	118.2	(38.1-275.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	2	2.6	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	9	5.1	177.6	(81.0-337.1)	Male	43	28.9	148.9	(107.7-200.6)
Female	5	4.2	119.6	(38.6-279.2)	Female	34	27.3	124.5	(86.2-173.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	16.4	85.3	(46.6-143.1)	Male	14	10.9	128.4	(70.1-215.4)
Female	6	5.7	104.9	(38.3-228.2)	Female	14	9.2	152.3	(83.2-255.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.0	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	9.6	93.6	(42.7-177.8)
Female	101	73.1	138.2	(112.5-167.9)	Female	13	8.0	163.3	(86.9-279.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.6	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	25.8	100.9	(65.9-147.9)	Female	9	7.6	118.7	(54.2-225.4)
Female	18	22.6	79.7	(47.2-126.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	4.6	nc	(nc-nc)	Male	64	70.7	90.5	(69.7-115.6)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.7	nc	(nc-nc)	Male	5	3.1	162.4	(52.3-378.9)
Female	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	8.1	nc	(nc-nc)	Female	17	14.9	114.5	(66.6-183.3)
Female	5	4.7	106.0	(34.1-247.3)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	3	3.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	9	5.9	153.8	(70.2-292.0)	Male	15	31.7	47.2	(26.4-77.9)
Female	3	4.5	nc	(nc-nc)	Female	23	28.3	81.2	(51.5-121.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

10

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.6	71.5	(32.6-135.8)	Male	7	7.0	100.3	(40.2-206.6)
Female	5	4.3	115.4	(37.2-269.4)	Female	2	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.4	296.1	(118.6-610.2)	Male	3	1.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.4	78.0	(25.1-182.1)
Female	45	44.5	101.0	(73.7-135.2)	Female	1	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	18.8	116.9	(73.2-176.9)	Female	4	4.8	nc	(nc-nc)
Female	16	16.8	95.3	(54.5-154.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male 7 3.6 196.0 (78.5-403.9)				
Male	4	3.2	nc	(nc-nc)	Female 2 3.6 nc (nc-nc)				
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male 48 49.9 96.1 (70.9-127.4)				
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male 6 3.2 189.1 (69.1-411.6)				
<u>Kidney & Renal Pelvis</u>					Female 2 1.8 nc (nc-nc)				
Male	11	5.3	206.2	(102.8-369.0)	<u>Testis</u>				
Female	5	3.2	156.9	(50.5-366.1)	Male 2 1.5 nc (nc-nc)				
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.1	nc	(nc-nc)	Male 1 1.5 nc (nc-nc)				
Female	0	0.6	nc	(nc-nc)	Female 4 4.6 nc (nc-nc)				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.9	nc	(nc-nc)	Female 6 9.3 64.7 (23.6-140.7)				
Female	2	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male 190 167.2 113.6 (98.0-131.0)				
Male	4	2.6	nc	(nc-nc)	Female 126 149.3 84.4 (70.3-100.5)				
Female	2	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	36	23.7	152.0	(106.4-210.4)					
Female	18	21.0	85.6	(50.7-135.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

11

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	12.6	127.4	(72.8-206.9)	Male	1	6.3	nc	(nc-nc)
Female	2	5.0	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	44	43.3	101.6	(73.8-136.4)	Female	5	6.1	81.7	(26.3-190.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	18.4	114.3	(70.8-174.8)	Female	3	4.8	nc	(nc-nc)
Female	27	19.9	136.0	(89.6-197.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.5	144.1	(46.4-336.3)
Male	6	3.1	196.4	(71.7-427.4)	Female	4	4.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	53	46.4	114.2	(85.5-149.4)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.2	nc	(nc-nc)
Male	9	4.9	184.4	(84.1-350.1)	<u>Testis</u>				
Female	5	3.3	149.5	(48.2-349.0)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.7	134.8	(43.4-314.5)	Female	9	9.0	100.0	(45.6-189.9)
Female	3	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	166	158.2	104.9	(89.6-122.2)
Male	2	2.3	nc	(nc-nc)	Female	164	156.2	105.0	(89.5-122.3)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	23.1	103.9	(66.6-154.6)					
Female	32	22.9	139.9	(95.7-197.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

12

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	34.3	110.8	(78.4-152.2)	Male	15	18.7	80.2	(44.8-132.2)
Female	14	14.2	98.8	(53.9-165.7)	Female	14	16.2	86.4	(47.2-145.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	4	5.6	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	17	17.3	98.2	(57.2-157.2)
Female	137	131.9	103.9	(87.2-122.8)	Female	25	17.7	141.0	(91.2-208.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.6	nc	(nc-nc)	Male	10	12.6	79.1	(37.9-145.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	51.1	101.7	(76.0-133.4)	Female	18	14.4	124.7	(73.9-197.1)
Female	61	57.5	106.0	(81.1-136.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	9.7	62.2	(22.7-135.3)
Male	2	8.6	nc	(nc-nc)	Female	14	12.2	114.6	(62.6-192.3)
Female	4	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	115	129.5	88.8	(73.3-106.6)
Male	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.1	nc	(nc-nc)	Male	5	8.7	57.2	(18.4-133.4)
<u>Kidney & Renal Pelvis</u>					Female	6	6.3	94.7	(34.6-206.1)
Male	15	14.1	106.7	(59.7-175.9)	<u>Testis</u>				
Female	11	9.7	113.5	(56.6-203.0)	Male	2	4.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	5.6	108.0	(39.4-235.0)	Male	4	3.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	14	12.7	110.3	(60.3-185.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	10.6	113.2	(58.4-197.7)	Female	25	27.2	92.0	(59.5-135.8)
Female	9	9.8	91.8	(41.9-174.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	412	445.2	92.5	(83.8-101.9)
Male	4	6.9	nc	(nc-nc)					
Female	1	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	67	62.9	106.6	(82.6-135.4)					

Female 63 64.2 98.1 (75.4-125.5)

Female 463 462.8 100.0 (91.1-109.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

13

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	5	2.1	242.1	(78.0-565.0)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	5	3.0	168.6	(54.3-393.4)
Female	0	0.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					

Lung and Bronchus

Male	1	1.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

All Sites / Types

Male	11	9.4	116.8	(58.2-209.1)
Female	10	6.6	151.8	(72.7-279.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

14

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.5	77.3	(39.9-135.1)	Male	8	9.3	86.4	(37.2-170.3)
Female	5	6.1	81.8	(26.4-190.9)	Female	9	8.1	110.6	(50.5-210.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.4	107.7	(49.1-204.4)
Female	51	63.5	80.3	(59.8-105.6)	Female	11	7.9	138.5	(69.0-247.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.0	nc	(nc-nc)	Male	8	6.2	129.3	(55.7-254.8)
<u>Colon / Rectum</u>					Female	4	3.1	nc	(nc-nc)
Male	17	23.5	72.4	(42.2-116.0)	<u>Ovary</u>				
Female	29	24.3	119.1	(79.8-171.1)	Female	4	6.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.0	198.0	(85.2-390.1)	Male	4	4.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	9	5.2	173.7	(79.3-329.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	66	61.6	107.2	(82.9-136.4)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.0	nc	(nc-nc)
Male	11	6.8	160.6	(80.1-287.4)	Female	1	2.6	nc	(nc-nc)
Female	6	4.5	134.5	(49.1-292.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	2.6	234.0	(85.5-509.4)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	7.1	nc	(nc-nc)
Male	5	5.2	97.0	(31.3-226.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.5	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	0	3.3	nc	(nc-nc)					
Female	2	1.2	nc	(nc-nc)	Female	18	12.9	139.9	(82.9-221.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	23	29.1	79.1	(50.1-118.7)	Male	204	210.9	96.7	(83.9-111.0)
Female	33	28.5	115.7	(79.6-162.4)	Female	213	213.6	99.7	(86.8-114.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

15

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	17.4	40.1	(16.1-82.7)	Male	9	11.2	80.1	(36.5-152.0)
Female	6	7.1	84.5	(30.9-184.0)	Female	10	11.1	90.2	(43.2-166.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.6	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	10.5	124.2	(66.1-212.4)
Female	80	74.4	107.5	(85.2-133.8)	Female	12	9.8	122.4	(63.2-213.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.7	133.5	(43.0-311.6)	Male	5	7.1	69.9	(22.5-163.2)
Female					Female	6	3.8	156.0	(57.0-339.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	26.6	97.9	(63.9-143.4)	Female	8	8.6	92.9	(40.0-183.1)
Female	20	28.5	70.1	(42.8-108.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	5.0	139.8	(56.0-288.1)
Male	6	4.5	133.2	(48.6-289.9)	Female	1	6.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	83	68.7	120.8	(96.2-149.8)
Male	2	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.5	nc	(nc-nc)	Male	5	4.6	109.8	(35.4-256.2)
<u>Kidney & Renal Pelvis</u>					Female	0	3.1	nc	(nc-nc)
Male	4	7.6	nc	(nc-nc)	<u>Testis</u>				
Female	2	5.3	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)					
<u>Leukemia</u>									
Male	8	6.9	115.3	(49.7-227.2)					

Female	4	5.8	nc	(nc-nc)	Female	5	11.0	45.4	(14.6-106.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.8	nc	(nc-nc)	Female	20	15.4	129.9	(79.3-200.6)
Female	2	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male	221	247.9	89.1	(77.8-101.7)
Male	14	32.4	43.3	(23.6-72.6)	Female	223	260.5	85.6	(74.7-97.6)
Female	15	33.1	45.3	(25.3-74.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

16

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	32.5	101.5	(69.8-142.5)	Male	15	19.2	78.0	(43.6-128.6)
Female	10	12.4	80.7	(38.7-148.5)	Female	26	16.3	159.4	(104.1-233.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.8	87.7	(32.0-190.9)	Male	4	5.1	nc	(nc-nc)
Female	4	5.7	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	16	17.4	91.9	(52.5-149.3)
Female	147	133.9	109.8	(92.8-129.0)	Female	21	16.2	130.0	(80.4-198.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.0	nc	(nc-nc)	Male	10	13.6	73.4	(35.1-135.0)
<u>Colon / Rectum</u>					Female	7	6.3	110.6	(44.3-228.0)
Male	38	49.7	76.5	(54.1-105.0)	<u>Ovary</u>				
Female	41	49.6	82.7	(59.4-112.2)	Female	7	14.2	49.2	(19.7-101.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	8.7	57.6	(18.6-134.4)	Male	13	9.5	137.5	(73.2-235.2)
Female	3	2.4	nc	(nc-nc)	Female	9	10.5	85.8	(39.1-162.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.6	nc	(nc-nc)	Male	168	133.6	125.7	(107.4-146.2)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	8.3	84.0	(33.6-173.0)
Male	10	14.7	68.2	(32.6-125.3)	Female	1	5.3	nc	(nc-nc)
Female	8	9.2	86.7	(37.3-170.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.3	nc	(nc-nc)
Male	2	5.7	nc	(nc-nc)					
Female	1	1.6	nc	(nc-nc)					

Leukemia

Male	10	10.7	93.7	(44.9-172.3)
Female	6	9.0	66.4	(24.2-144.5)

Liver and Intrahepatic Bile Ducts

Male	5	7.2	69.1	(22.3-161.3)
Female	1	2.5	nc	(nc-nc)

Lung and Bronchus

Male	44	61.6	71.4	(51.9-95.9)
Female	36	58.5	61.5	(43.1-85.1)

Thyroid

Male	5	4.2	118.6	(38.2-276.8)
Female	22	14.1	156.3	(97.9-236.7)

Uteri Corpus and Uterus, NOS

Female	21	27.5	76.5	(47.3-116.9)
--------	----	------	------	--------------

All Sites / Types

Male	422	447.2	94.4	(85.6-103.8)
Female	404	440.4	91.7	(83.0-101.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

17

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
Esophagus					Pancreas				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.0	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Larynx					Testis				

Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	3.9	305.9	(157.9-534.4)
Female	0	0.5	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

18

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	49.4	105.2	(78.6-138.0)	Male	31	27.1	114.4	(77.7-162.4)
Female	20	21.0	95.2	(58.1-147.0)	Female	23	25.0	91.8	(58.2-137.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	9.0	111.3	(53.3-204.8)	Male	9	7.4	121.3	(55.4-230.3)
Female	6	8.5	71.0	(25.9-154.5)	Female	9	6.7	135.0	(61.6-256.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	26	24.9	104.3	(68.1-152.9)
Female	200	199.2	100.4	(87.0-115.3)	Female	27	26.5	101.7	(67.0-148.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	8.8	68.0	(24.8-147.9)	Male	18	17.8	101.3	(60.0-160.2)
Female	6	8.8	68.0	(24.8-147.9)	Female	7	9.9	70.4	(28.2-145.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	63	73.2	86.0	(66.1-110.1)	Female	17	21.6	78.5	(45.7-125.8)
Female	77	83.7	92.0	(72.6-115.0)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	12.3	56.7	(22.7-116.8)	Male	8	13.8	58.0	(25.0-114.3)
Female	5	4.1	122.5	(39.5-285.8)	Female	18	17.9	100.4	(59.5-158.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.7	nc	(nc-nc)	Male	176	189.0	93.1	(79.9-107.9)
Female	4	3.3	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	21	20.2	103.7	(64.2-158.6)	Male	9	12.5	71.9	(32.8-136.4)

Female	10	14.6	68.3	(32.7-125.5)	Female	6	9.1	66.0	(24.1-143.7)
<u>Larynx</u>					<u>Testis</u>				
Male	13	8.0	162.7	(86.6-278.3)	Male	7	6.7	104.0	(41.7-214.3)
Female	5	2.5	198.4	(63.9-463.1)	<u>Thyroid</u>				
<u>Leukemia</u>					Male	10	5.7	176.0	(84.3-323.7)
Male	17	15.2	111.5	(64.9-178.6)	Female	29	20.2	143.4	(96.0-205.9)
Female	12	14.5	82.8	(42.7-144.6)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	43	41.0	104.9	(75.9-141.2)
Male	10	9.8	101.9	(48.8-187.4)	<u>All Sites / Types</u>				
Female	5	4.2	119.4	(38.5-278.6)	Male	602	644.5	93.4	(86.1-101.2)
<u>Lung and Bronchus</u>					Female	664	694.3	95.6	(88.5-103.2)
Male	65	91.7	70.9	(54.7-90.4)					
Female	82	97.7	83.9	(66.8-104.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

19

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.8	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	16	19.1	83.6	(47.7-135.8)	Female	3	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	9	7.4	121.2	(55.3-230.0)	<u>Ovary</u>				
Female	8	6.0	134.0	(57.7-264.1)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	17	20.2	84.4	(49.1-135.1)
Female	0	0.4	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	5	2.3	216.2	(69.7-504.7)
Female	1	1.2	nc	(nc-nc)

Larynx

Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Leukemia

Male	2	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.2	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)

Lung and Bronchus

Male	6	9.2	65.3	(23.8-142.2)
Female	6	7.6	79.1	(28.9-172.3)

Stomach

Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Testis

Male	2	0.9	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.7	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	2	3.8	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	61	68.4	89.2	(68.2-114.5)
Female	59	59.8	98.7	(75.2-127.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

20

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	6	10.1	59.5	(21.7-129.5)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	8	3.8	210.0	(90.4-413.8)	<u>Ovary</u>				
Female	8	3.4	237.7	(102.3-468.3)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	0	0.2	nc	(nc-nc)	Male	13	10.5	123.9	(65.9-211.9)
Female	1	0.2	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	4.8	nc	(nc-nc)	Male	35	35.3	99.1	(69.0-137.8)
Female	6	4.2	143.5	(52.4-312.3)	Female	36	32.2	111.8	(78.3-154.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

21 Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	7.8	102.0	(43.9-201.0)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
					Female	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)

Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	8.1	135.1	(67.4-241.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	31	27.8	111.6	(75.8-158.5)
Male	0	0.5	nc	(nc-nc)	Female	21	24.4	86.0	(53.2-131.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.8	nc	(nc-nc)					
Female	2	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

22

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	13.3	150.5	(91.9-232.4)	Male	12	8.4	143.0	(73.8-249.8)
Female	4	4.6	nc	(nc-nc)	Female	7	7.2	97.6	(39.1-201.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.5	80.3	(29.3-174.9)
Female	60	55.9	107.3	(81.9-138.1)	Female	9	6.3	143.0	(65.3-271.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.8	nc	(nc-nc)	Male	5	5.7	87.1	(28.1-203.2)
<u>Colon / Rectum</u>					Female	0	2.5	nc	(nc-nc)
Male	23	20.5	112.2	(71.1-168.4)	<u>Ovary</u>				
Female	18	17.6	102.1	(60.5-161.4)	Female	6	5.8	103.1	(37.6-224.3)

Esophagus

Male	4	3.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	1.3	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)

Kidney & Renal Pelvis

Male	1	6.3	nc	(nc-nc)
Female	0	3.7	nc	(nc-nc)

Larynx

Male	4	2.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)

Leukemia

Male	4	4.6	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	3	3.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)

Lung and Bronchus

Male	12	25.6	46.9	(24.2-81.9)
Female	24	22.9	104.6	(67.0-155.7)

Pancreas

Male	5	3.9	128.9	(41.6-300.9)
Female	9	3.8	239.1	(109.1-453.9)

Prostate

Male	49	55.4	88.5	(65.5-117.0)
------	----	------	------	--------------

Stomach

Male	4	3.4	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)

Testis

Male	2	2.4	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	2.0	nc	(nc-nc)
Female	5	6.8	73.6	(23.7-171.7)

Uteri Corpus and Uterus, NOS

Female	10	11.4	87.6	(41.9-161.1)
--------	----	------	------	--------------

All Sites / Types

Male	168	187.6	89.5	(76.5-104.2)
Female	171	176.3	97.0	(83.0-112.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.2	98.9	(54.0-165.9)	Male	7	7.5	93.8	(37.6-193.3)
Female	5	5.5	90.5	(29.2-211.3)	Female	4	6.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	7.0	85.8	(31.3-186.7)
Female	44	49.7	88.6	(64.4-118.9)	Female	7	6.9	101.7	(40.8-209.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
					Female	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				

Female	1	7.7	nc	(nc-nc)	Female	8	8.0	99.6	(42.9-196.2)
Colon / Rectum					Ovary				
Male	53	61.2	86.6	(64.9-113.3)	Female	18	17.7	101.7	(60.3-160.8)
Female	62	65.6	94.5	(72.4-121.1)	Pancreas				
Esophagus					Male	7	11.6	60.5	(24.2-124.6)
Male	17	10.5	162.1	(94.4-259.5)	Female	11	14.0	78.7	(39.2-140.8)
Female	2	3.2	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	141	160.2	88.0	(74.1-103.8)
Male	5	3.7	133.9	(43.1-312.4)	Stomach				
Female	2	3.2	nc	(nc-nc)	Male	12	10.4	115.2	(59.5-201.2)
Kidney & Renal Pelvis					Female	6	7.1	84.1	(30.7-183.0)
Male	21	17.7	118.9	(73.6-181.7)	Testis				
Female	10	11.8	84.9	(40.7-156.2)	Male	7	6.9	101.0	(40.4-208.0)
Larynx					Thyroid				
Male	4	6.8	nc	(nc-nc)	Male	6	5.4	111.6	(40.7-242.8)
Female	3	2.0	nc	(nc-nc)	Female	18	18.1	99.3	(58.8-157.0)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	12	13.5	89.0	(45.9-155.5)	Female	30	33.4	89.8	(60.6-128.3)
Female	11	11.9	92.1	(45.9-164.8)	All Sites / Types				
Liver and Intrahepatic Bile Ducts					Male	535	549.2	97.4	(89.3-106.0)
Male	12	8.5	141.0	(72.8-246.3)	Female	529	561.6	94.2	(86.3-102.6)
Female	4	3.3	nc	(nc-nc)					
Lung and Bronchus									
Male	90	76.1	118.3	(95.1-145.4)					
Female	84	76.5	109.9	(87.6-136.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

25

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	25	21.9	114.0	(73.7-168.3)	Male	4	11.5	nc	(nc-nc)
Female	10	8.2	122.3	(58.6-225.0)	Female	3	9.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	3.8	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	5	3.2	154.4	(49.8-360.3)	Female	1	2.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	11	10.7	102.6	(51.1-183.5)
Female	60	77.0	77.9	(59.5-100.3)	Female	9	10.2	87.9	(40.1-166.8)

Cervix Uteri

Female	1	3.2	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	35	32.4	108.0	(75.2-150.2)
------	----	------	-------	--------------

Female	28	32.5	86.3	(57.3-124.7)
--------	----	------	------	--------------

Esophagus

Male	8	5.4	147.0	(63.3-289.6)
------	---	-----	-------	--------------

Female	1	1.6	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	2	1.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	1.2	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	4	8.8	nc	(nc-nc)
------	---	-----	----	---------

Female	10	5.7	175.5	(84.0-322.8)
--------	----	-----	-------	--------------

Larynx

Male	2	3.5	nc	(nc-nc)
------	---	-----	----	---------

Female	1	1.0	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	2	6.6	nc	(nc-nc)
------	---	-----	----	---------

Female	6	5.6	107.5	(39.2-233.9)
--------	---	-----	-------	--------------

Liver and Intrahepatic Bile Ducts

Male	7	4.3	164.6	(66.0-339.2)
------	---	-----	-------	--------------

Female	0	1.6	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	31	40.5	76.6	(52.0-108.7)
------	----	------	------	--------------

Female	51	38.2	133.7	(99.5-175.8)
--------	----	------	-------	--------------

Oral Cavity & Pharynx

Male	9	7.7	116.6	(53.2-221.4)
------	---	-----	-------	--------------

Female	6	3.8	156.1	(57.0-339.8)
--------	---	-----	-------	--------------

Ovary

Female	4	8.4	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	5	6.1	81.6	(26.3-190.5)
------	---	-----	------	--------------

Female	7	7.0	100.6	(40.3-207.2)
--------	---	-----	-------	--------------

Prostate

Male	62	83.2	74.5	(57.1-95.5)
------	----	------	------	-------------

Stomach

Male	2	5.5	nc	(nc-nc)
------	---	-----	----	---------

Female	4	3.5	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	5	2.3	220.7	(71.1-515.0)
------	---	-----	-------	--------------

Thyroid

Male	3	2.3	nc	(nc-nc)
------	---	-----	----	---------

Female	2	7.3	nc	(nc-nc)
--------	---	-----	----	---------

Uteri Corpus and Uterus, NOS

Female	25	16.1	155.7	(100.7-229.8)
--------	----	------	-------	---------------

All Sites / Types

Male	237	281.8	84.1	(73.7-95.5)
------	-----	-------	------	-------------

Female	255	268.1	95.1	(83.8-107.5)
--------	-----	-------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

26

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.8	104.1	(38.0-226.7)	Male	4	3.1	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	13	20.6	63.0	(33.5-107.7)	Female	4	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	10	8.5	117.6	(56.3-216.3)	<u>Ovary</u>				
Female	14	8.1	173.8	(95.0-291.7)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	20	22.6	88.5	(54.1-136.7)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.0	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	77	75.1	102.5	(80.9-128.1)
Female	0	0.4	nc	(nc-nc)	Female	82	70.5	116.4	(92.6-144.5)
<u>Lung and Bronchus</u>									

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

27

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.3	79.3	(25.6-185.1)	Male	0	3.8	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)

Female	0	1.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	21	25.9	81.1	(50.2-124.0)	Female	4	3.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Colon / Rectum					Female	1	1.3	nc	(nc-nc)
Male	10	9.5	105.1	(50.3-193.3)	Ovary				
Female	7	10.6	65.9	(26.4-135.8)	Female	8	2.8	283.1	(121.9-557.9)
Esophagus					Pancreas				
Male	1	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.7	nc	(nc-nc)	Male	22	25.0	88.2	(55.2-133.5)
Female	0	0.5	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	1.6	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Testis				
Larynx					Male	1	1.3	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Thyroid				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Leukemia					Female	5	3.0	168.8	(54.4-393.8)
Male	1	2.1	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Female	3	2.0	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	1	1.3	nc	(nc-nc)	Male	73	86.2	84.7	(66.4-106.4)
Female	2	0.5	nc	(nc-nc)	Female	86	90.0	95.5	(76.4-118.0)
Lung and Bronchus									
Male	14	11.9	117.9	(64.4-197.8)					
Female	19	12.2	155.9	(93.8-243.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

28

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	75	73.9	101.4	(79.8-127.2)	Male	56	37.0	151.3	(114.3-196.4)
Female	24	25.5	94.0	(60.2-139.9)	Female	51	28.5	179.2	(133.4-235.6)

Brain and Other Nervous System

Male	11	11.9	92.1	(45.9-164.9)
Female	14	9.9	141.2	(77.1-237.0)

Breast

Male	1	2.1	nc	(nc-nc)
Female	253	237.1	106.7	(93.9-120.7)

Cervix Uteri

Female	9	9.7	92.7	(42.3-176.1)
--------	---	-----	------	--------------

Colon / Rectum

Male	98	107.8	90.9	(73.8-110.8)
Female	108	99.9	108.1	(88.7-130.5)

Esophagus

Male	13	17.9	72.7	(38.7-124.4)
Female	5	5.0	100.7	(32.4-234.9)

Hodgkin Lymphoma

Male	5	4.3	115.1	(37.1-268.6)
Female	4	3.6	nc	(nc-nc)

Kidney & Renal Pelvis

Male	37	28.4	130.5	(91.9-179.8)
Female	19	17.8	106.9	(64.3-166.9)

Larynx

Male	8	11.4	70.0	(30.1-137.9)
Female	4	3.1	nc	(nc-nc)

Leukemia

Male	27	21.6	125.2	(82.5-182.1)
Female	28	17.0	164.3	(109.1-237.5)

Liver and Intrahepatic Bile Ducts

Male	13	13.7	94.9	(50.5-162.4)
Female	8	5.0	159.2	(68.5-313.7)

Lung and Bronchus

Male	123	135.3	90.9	(75.6-108.5)
Female	120	120.7	99.4	(82.4-118.9)

Multiple Myeloma

Male	9	10.9	82.9	(37.8-157.4)
Female	7	8.1	86.4	(34.6-178.0)

Non-Hodgkin Lymphoma

Male	34	34.9	97.3	(67.4-136.0)
Female	21	31.7	66.3	(41.0-101.3)

Oral Cavity & Pharynx

Male	25	24.3	102.7	(66.5-151.6)
Female	14	11.9	117.9	(64.4-197.8)

Ovary

Female	23	25.8	89.1	(56.4-133.6)
--------	----	------	------	--------------

Pancreas

Male	26	20.3	127.9	(83.5-187.5)
Female	38	21.7	175.5	(124.2-240.9)

Prostate

Male	372	273.1	136.2	(122.7-150.8)
------	-----	-------	-------	---------------

Stomach

Male	17	18.5	91.9	(53.5-147.2)
Female	12	10.7	112.3	(57.9-196.1)

Testis

Male	8	6.7	119.7	(51.6-235.9)
------	---	-----	-------	--------------

Thyroid

Male	4	6.9	nc	(nc-nc)
Female	11	21.8	50.5	(25.2-90.4)

Uteri Corpus and Uterus, NOS

Female	45	49.7	90.5	(66.0-121.2)
--------	----	------	------	--------------

All Sites / Types

Male	1034	927.1	111.5	(104.8-118.5)
Female	879	828.5	106.1	(99.2-113.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				

Male	1	5.4	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	17	19.4	87.5	(50.9-140.0)	Female	3	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	6	8.1	73.7	(26.9-160.3)	<u>Ovary</u>				
Female	3	7.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	20.5	63.5	(33.8-108.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.1	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	50	71.7	69.7	(51.8-91.9)
Female	0	0.4	nc	(nc-nc)	Female	50	65.9	75.9	(56.4-100.1)
<u>Lung and Bronchus</u>									
Male	13	10.0	129.7	(69.0-221.8)					
Female	9	8.9	100.6	(45.9-191.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	9	7.1	126.4	(57.7-239.9)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Lung and Bronchus</u>				
Male	6	4.4	135.1	(49.3-294.0)	Male	23	31.5	72.9	(46.2-109.4)
Female	3	3.1	nc	(nc-nc)	Female	26	22.8	113.9	(74.4-166.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	20.5	63.4	(33.7-108.5)	Male	16	10.3	155.1	(88.6-251.9)
Female	5	5.9	85.2	(27.4-198.7)	Female	10	6.8	146.2	(70.0-268.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.7	144.1	(78.7-241.8)
Female	60	56.8	105.6	(80.6-136.0)	Female	4	7.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	29.9	83.5	(54.0-123.3)	Female	9	6.1	146.6	(66.9-278.3)
Female	19	23.3	81.4	(49.0-127.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	5.0	nc	(nc-nc)	Male	64	75.4	84.9	(65.4-108.4)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	7.9	88.4	(35.4-182.1)	Female	13	11.9	109.6	(58.3-187.5)
Female	3	4.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Lung and Bronchus</u>				
Male	1	3.2	nc	(nc-nc)	Male	23	37.4	61.5	(39.0-92.4)
Female	0	0.7	nc	(nc-nc)	Female	21	27.1	77.4	(47.9-118.3)
<u>Leukemia</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	4	6.0	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.0	90.9	(43.5-167.2)	Male	9	7.0	128.9	(58.8-244.7)
Female	4	3.7	nc	(nc-nc)	Female	10	6.0	166.8	(79.8-306.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.6	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	5	2.0	246.3	(79.4-574.8)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	6.3	79.8	(25.7-186.2)
Female	44	45.9	95.8	(69.6-128.6)	Female	6	5.2	115.1	(42.0-250.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	16.9	100.3	(58.4-160.6)	Female	4	4.8	nc	(nc-nc)
Female	9	14.7	61.0	(27.9-115.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	6	2.9	204.2	(74.6-444.6)	Male	34	43.6	78.0	(54.0-109.0)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.1	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	5.1	nc	(nc-nc)	Female	11	9.2	120.1	(59.9-214.9)
Female	6	3.0	198.4	(72.4-431.7)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	4	3.8	nc	(nc-nc)	Male	16	20.7	77.4	(44.2-125.7)
Female	2	2.9	nc	(nc-nc)	Female	19	18.5	103.0	(62.0-160.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

33

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.4	104.7	(57.2-175.6)	Male	8	8.5	94.7	(40.8-186.5)
Female	5	4.7	107.0	(34.5-249.7)	Female	8	7.1	112.8	(48.5-222.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.5	66.6	(21.5-155.4)
Female	43	55.3	77.7	(56.2-104.7)	Female	8	6.4	125.8	(54.2-248.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	8	5.8	137.3	(59.1-270.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	20.6	111.5	(70.7-167.3)	Female	8	5.8	138.0	(59.4-272.0)
Female	12	17.9	67.2	(34.7-117.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	3.7	nc	(nc-nc)	Male	49	57.3	85.5	(63.3-113.1)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.3	94.7	(34.6-206.1)	Female	11	11.5	96.0	(47.8-171.7)
Female	3	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	5	2.4	205.6	(66.3-479.8)	Male	6	4.6	130.1	(47.5-283.2)
Female	0	0.7	nc	(nc-nc)	Female	5	3.5	141.5	(45.6-330.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	3.1	nc	(nc-nc)	Male	34	25.9	131.1	(90.8-183.2)
Female	0	0.9	nc	(nc-nc)	Female	37	23.5	157.7	(111.0-217.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

34

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.4	98.7	(66.6-140.9)	Male	21	16.1	130.1	(80.5-198.8)
Female	5	11.6	43.0	(13.9-100.4)	Female	24	13.8	173.7	(111.3-258.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.4	93.2	(30.0-217.5)	Male	2	4.5	nc	(nc-nc)
Female	5	4.8	105.2	(33.9-245.6)	Female	0	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	13	15.0	86.6	(46.0-148.0)
Female	121	112.4	107.7	(89.3-128.7)	Female	23	14.7	156.2	(99.0-234.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.9	nc	(nc-nc)	Male	7	10.8	64.8	(26.0-133.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	44.9	86.9	(61.8-118.7)	Female	17	12.2	139.6	(81.2-223.4)
Female	52	46.7	111.4	(83.2-146.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	8.5	106.2	(48.5-201.6)
Male	6	7.5	79.7	(29.1-173.4)	Female	15	9.9	151.0	(84.4-249.0)
Female	4	2.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	102	114.8	88.9	(72.5-107.9)
Male	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.8	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	5.1	nc	(nc-nc)
Male	6	12.2	49.2	(18.0-107.2)	<u>Testis</u>				
Female	6	8.2	73.5	(26.8-160.0)	Male	6	3.4	179.0	(65.3-389.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.9	nc	(nc-nc)	Male	5	3.2	155.4	(50.1-362.7)
Female	0	1.4	nc	(nc-nc)	Female	11	11.1	98.7	(49.2-176.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	9.2	86.6	(37.3-170.6)	Female	21	23.1	90.8	(56.2-138.8)
Female	13	8.1	160.8	(85.6-275.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	322	390.9	82.4	(73.6-91.9)
Male	3	5.9	nc	(nc-nc)	Female	400	387.6	103.2	(93.3-113.8)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	55.7	50.2	(33.4-72.6)					
Female	38	53.8	70.7	(50.0-97.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

35

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.0	126.1	(40.6-294.2)	Male	3	2.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	17	17.3	98.2	(57.1-157.2)	Female	3	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	6.3	127.3	(54.8-250.9)	Female	2	1.8	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	22	17.3	126.9	(79.5-192.2)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.1	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	1	1.5	nc	(nc-nc)	Male	7	7.8	90.3	(36.2-186.1)
Female	0	1.1	nc	(nc-nc)					

Female 7 6.4 109.5 (43.9-225.6)

Female 56 53.5 104.7 (79.1-136.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

36

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	16	10.2	156.4	(89.4-254.1)	Female	1	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	5	3.5	142.3	(45.9-332.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male 2 0.8 nc (nc-nc)				
Male	0	0.7	nc	(nc-nc)	Female 0 0.8 nc (nc-nc)				
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male 13 11.5 112.9 (60.1-193.2)				
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male 1 0.7 nc (nc-nc)				
<u>Kidney & Renal Pelvis</u>					Female 0 0.4 nc (nc-nc)				
Male	2	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.7	nc	(nc-nc)	Male 1 0.4 nc (nc-nc)				
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male 0 0.4 nc (nc-nc)				
Female	0	0.1	nc	(nc-nc)	Female 3 1.1 nc (nc-nc)				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female 3 2.1 nc (nc-nc)				
Female	0	0.7	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.6	nc	(nc-nc)					
Female	1	0.2	nc	(nc-nc)					

Lung and Bronchus

Male	4	5.2	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)

All Sites / Types

Male	36	37.7	95.4	(66.8-132.1)
Female	40	33.1	121.0	(86.5-164.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

37

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.9	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	14	10.1	138.3	(75.5-232.1)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	4.3	161.9	(64.9-333.7)	Female	2	1.1	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	14	11.5	122.1	(66.7-204.9)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.4	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	9	2.1	427.6	(195.1-811.9)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	5.5	nc	(nc-nc)	Male	39	38.2	102.1	(72.6-139.6)
Female	2	4.7	nc	(nc-nc)	Female	40	33.9	118.0	(84.3-160.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

38

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	44.9	113.7	(84.6-149.5)	Male	24	24.8	96.8	(62.0-144.1)
Female	19	18.5	102.6	(61.7-160.2)	Female	29	21.7	133.4	(89.3-191.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	8.4	178.0	(99.6-293.6)	Male	7	6.8	103.6	(41.5-213.5)
Female	9	7.5	119.7	(54.6-227.2)	Female	3	5.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.3	nc	(nc-nc)	Male	16	22.8	70.0	(40.0-113.7)
Female	172	172.9	99.5	(85.2-115.5)	Female	28	23.3	120.1	(79.8-173.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	7.6	nc	(nc-nc)	Male	19	16.5	115.3	(69.4-180.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	53	66.7	79.4	(59.5-103.9)	Female	27	19.0	142.3	(93.8-207.1)
Female	84	75.0	112.0	(89.3-138.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	12.6	103.3	(55.0-176.7)
Male	12	11.2	106.7	(55.1-186.4)	Female	13	15.9	81.6	(43.4-139.5)
Female	2	3.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	136	170.6	79.7	(66.9-94.3)
Male	5	3.5	144.0	(46.4-336.0)	<u>Stomach</u>				
Female	2	3.1	nc	(nc-nc)	Male	5	11.4	43.8	(14.1-102.3)
<u>Kidney & Renal Pelvis</u>					Female	3	8.3	nc	(nc-nc)
Male	22	18.5	118.9	(74.5-180.0)	<u>Testis</u>				
Female	22	12.7	172.6	(108.1-261.3)	Male	9	6.0	149.4	(68.2-283.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	7.3	165.0	(85.1-288.2)	Male	5	5.2	96.6	(31.1-225.5)
Female	5	2.2	232.6	(74.9-542.7)					
<u>Leukemia</u>									
Male	10	14.1	71.0	(34.0-130.6)					

Female 15 13.1 114.8 (64.2-189.4)

Liver and Intrahepatic Bile Ducts

Male 7 9.0 77.4 (31.0-159.4)

Female 4 3.7 nc (nc-nc)

Lung and Bronchus

Male 77 82.8 93.0 (73.4-116.3)

Female 102 84.0 121.4 (99.0-147.4)

Female 18 17.5 102.8 (60.9-162.5)

Uteri Corpus and Uterus, NOS

Female 39 35.3 110.6 (78.6-151.2)

All Sites / Types

Male 539 586.2 92.0 (84.4-100.1)

Female 661 608.2 108.7 (100.6-117.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	31.5	88.9	(59.1-128.5)	Male	23	21.0	109.7	(69.5-164.6)
Female	11	11.2	98.4	(49.1-176.2)	Female	14	17.2	81.3	(44.4-136.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.7	64.7	(20.8-150.9)	Male	7	5.0	138.9	(55.6-286.2)
Female	5	5.9	84.8	(27.3-197.9)	Female	5	3.5	141.2	(45.5-329.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	19	18.4	103.2	(62.1-161.1)
Female	128	134.8	95.0	(79.2-112.9)	Female	11	15.3	71.9	(35.9-128.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.7	nc	(nc-nc)	Male	16	14.7	108.7	(62.1-176.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	49.4	85.1	(61.3-115.0)	Female	17	14.1	120.3	(70.1-192.7)
Female	38	43.1	88.2	(62.4-121.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	9.5	63.4	(23.2-138.0)
Male	11	8.9	123.5	(61.6-221.1)	Female	8	9.2	87.1	(37.5-171.5)
Female	1	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	165	139.8	118.0	(100.7-137.5)
Male	4	3.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.6	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	4.5	nc	(nc-nc)
Male	21	15.6	134.3	(83.1-205.3)	<u>Testis</u>				
Female	7	9.0	78.2	(31.3-161.0)	Male	6	6.7	89.6	(32.7-195.0)
<u>Larynx</u>									
Male	3	6.0	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

Leukemia

Male	8	11.3	70.9	(30.5-139.8)
Female	12	8.5	141.1	(72.8-246.5)

Liver and Intrahepatic Bile Ducts

Male	4	7.6	nc	(nc-nc)
Female	7	2.3	304.1	(121.8-626.6)

Lung and Bronchus

Male	84	61.6	136.3	(108.7-168.8)
Female	76	55.6	136.7	(107.7-171.2)

Thyroid

Male	5	5.2	96.4	(31.1-225.0)
Female	16	16.2	98.9	(56.5-160.5)

Uteri Corpus and Uterus, NOS

Female	25	28.2	88.5	(57.3-130.7)
--------	----	------	------	--------------

All Sites / Types

Male	501	463.7	108.1	(98.8-117.9)
Female	439	427.6	102.7	(93.3-112.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

40

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	11	7.5	145.8	(72.7-261.0)	Male	4	4.7	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	26	30.8	84.4	(55.1-123.7)	Female	6	3.7	160.8	(58.7-350.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.5	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	11	11.5	95.6	(47.7-171.1)	Female	4	3.3	nc	(nc-nc)
Female	12	10.8	110.9	(57.3-193.8)	Pancreas				
Esophagus					Male	2	2.2	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
Female	4	0.5	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	23	30.0	76.6	(48.6-115.0)
Male	2	0.8	nc	(nc-nc)	Stomach				
Female	1	0.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Kidney & Renal Pelvis					Female	3	1.1	nc	(nc-nc)
Male	8	3.4	233.8	(100.7-460.7)	Testis				
Female	4	2.1	nc	(nc-nc)					
Larynx									

Male	0	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	2.6	267.7	(107.3-551.6)	Male	2	1.1	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.7	nc	(nc-nc)	Female	6	6.2	96.1	(35.1-209.2)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	22	14.2	155.2	(97.2-234.9)	Male	98	104.2	94.0	(76.3-114.6)
Female	16	13.5	118.3	(67.6-192.1)	Female	105	101.2	103.7	(84.8-125.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

41

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	5	4.7	105.6	(34.0-246.5)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
					Female	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	5.5	128.2	(51.4-264.2)
Female	0	0.1	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)

Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Male	12	18.0	66.6	(34.4-116.3)
<u>Lung and Bronchus</u>					Female	18	14.5	124.0	(73.4-195.9)
Male	1	2.5	nc	(nc-nc)					
Female	4	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

42

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.2	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	18	14.4	124.9	(74.0-197.5)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	5.1	nc	(nc-nc)	<u>Ovary</u>				
Female	7	3.8	182.0	(72.9-375.1)	Female	2	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	12	14.6	82.1	(42.4-143.5)
Female	1	0.3	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	2	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Larynx

Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Leukemia

Male	0	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Lung and Bronchus

Male	3	6.3	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)

Stomach

Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Testis

Male	2	0.6	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	2	0.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	1	2.9	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	44	48.4	90.9	(66.0-122.0)
Female	42	42.6	98.6	(71.1-133.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

43

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	339	456.4	74.3	(66.6-82.6)	Male	229	278.0	82.4	(72.0-93.8)
Female	155	185.8	83.4	(70.8-97.6)	Female	203	263.1	77.2	(66.9-88.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	66	100.5	65.7	(50.8-83.6)	Male	78	69.9	111.6	(88.2-139.3)
Female	72	88.6	81.3	(63.6-102.4)	Female	73	58.6	124.6	(97.7-156.7)
Breast					Non-Hodgkin Lymphoma				
Male	19	13.9	137.0	(82.5-214.0)	Male	280	252.2	111.0	(98.4-124.8)
Female	1822	1887.7	96.5	(92.1-101.1)	Female	230	246.9	93.2	(81.5-106.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	126	95.2	132.4	(110.3-157.6)	Male	233	177.0	131.6	(115.3-149.7)
Colon / Rectum					Ovary				
Male	715	688.4	103.9	(96.4-111.8)	Female	189	206.8	91.4	(78.8-105.4)
Female	815	735.2	110.9	(103.4-118.7)	Pancreas				
Esophagus					Male	151	129.5	116.6	(98.7-136.8)
Male	103	117.0	88.0	(71.9-106.8)	Female	149	156.9	95.0	(80.3-111.5)
Female	39	36.0	108.4	(77.1-148.2)	Prostate				
Hodgkin Lymphoma									

Male	39	54.6	71.4	(50.8-97.7)	Male	1979	1776.1	111.4	(106.6-116.4)
Female	54	49.3	109.5	(82.2-142.8)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	202	197.4	102.3	(88.7-117.4)	Male	160	118.1	135.5	(115.3-158.2)
Female	150	135.8	110.4	(93.5-129.6)	Female	131	79.5	164.8	(137.7-195.5)
<u>Larynx</u>					<u>Testis</u>				
Male	88	76.1	115.6	(92.7-142.5)	Male	79	105.7	74.8	(59.2-93.2)
Female	25	23.5	106.6	(68.9-157.3)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	145	158.2	91.7	(77.4-107.9)	Male	78	65.5	119.1	(94.2-148.7)
Female	136	139.3	97.6	(81.9-115.5)	Female	298	239.6	124.4	(110.7-139.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	174	95.4	182.4	(156.3-211.6)	Female	363	388.0	93.6	(84.2-103.7)
Female	56	37.9	147.7	(111.6-191.9)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	984	850.1	115.8	(108.6-123.2)	Male	6679	6227.5	107.3	(104.7-109.9)
Female	905	875.1	103.4	(96.8-110.4)	Female	6657	6519.0	102.1	(99.7-104.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

44

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	25.4	106.1	(69.9-154.4)	Male	15	13.2	113.4	(63.4-187.1)
Female	12	9.0	133.1	(68.7-232.4)	Female	10	10.3	96.7	(46.3-177.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.4	nc	(nc-nc)	Male	9	3.8	239.0	(109.1-453.8)
Female	4	3.6	nc	(nc-nc)	Female	5	2.9	175.0	(56.4-408.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	12.4	96.9	(50.0-169.4)
Female	92	84.4	109.0	(87.9-133.7)	Female	13	11.3	115.5	(61.4-197.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.5	nc	(nc-nc)	Male	11	8.7	126.0	(62.8-225.5)
					Female	6	4.2	141.2	(51.6-307.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	44	37.4	117.7	(85.5-158.0)	Female	8	9.2	86.7	(37.3-170.8)
Female	44	35.3	124.6	(90.5-167.2)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.3	95.6	(34.9-208.0)	Male	2	7.1	nc	(nc-nc)

Female	1	1.8	nc	(nc-nc)	Female	5	7.6	65.5	(21.1-152.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.8	nc	(nc-nc)	Male	127	96.9	131.1	(109.3-156.0)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.4	94.1	(34.4-204.8)
Male	9	10.1	89.4	(40.8-169.7)	Female	3	3.8	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.0	nc	(nc-nc)
Male	6	4.0	148.5	(54.2-323.2)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	8.1	61.7	(19.9-144.0)
Male	11	7.7	142.7	(71.1-255.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.1	nc	(nc-nc)	Female	26	17.8	145.9	(95.3-213.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.9	123.2	(45.0-268.2)	Male	380	327.0	116.2	(104.8-128.5)
Female	3	1.8	nc	(nc-nc)	Female	348	295.1	117.9	(105.9-131.0)
<u>Lung and Bronchus</u>									
Male	51	47.2	108.1	(80.5-142.1)					
Female	68	42.5	159.9	(124.2-202.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

45

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	16	14.5	110.4	(63.1-179.4)	Female	3	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.5	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)

Esophagus

Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Kidney & Renal Pelvis

Male	1	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Larynx

Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Leukemia

Male	1	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Lung and Bronchus

Male	3	5.9	nc	(nc-nc)
Female	3	4.7	nc	(nc-nc)

Pancreas

Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Prostate

Male	13	13.4	97.1	(51.6-166.0)
------	----	------	------	--------------

Stomach

Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Testis

Male	2	0.8	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	4	0.6	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	5	2.8	175.6	(56.6-409.9)
--------	---	-----	-------	--------------

All Sites / Types

Male	35	46.9	74.6	(51.9-103.7)
Female	48	41.8	114.9	(84.7-152.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

46

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.8	nc	(nc-nc)	Male	10	4.8	208.0	(99.6-382.5)
Female	3	2.3	nc	(nc-nc)	Female	5	3.6	138.1	(44.5-322.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.3	185.9	(80.0-366.3)
Female	42	30.1	139.6	(100.6-188.7)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
					Female	4	1.3	nc	(nc-nc)

Male	18	12.1	149.1	(88.3-235.6)					
Female	8	9.0	89.1	(38.4-175.5)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	28	33.6	83.4	(55.4-120.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	6	6.1	97.8	(35.7-212.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.8	nc	(nc-nc)	Male	97	110.7	87.6	(71.1-106.9)
Female	0	0.5	nc	(nc-nc)	Female	100	91.9	108.8	(88.5-132.4)
<u>Lung and Bronchus</u>									
Male	7	15.1	46.5	(18.6-95.7)					
Female	11	11.7	94.0	(46.9-168.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

47

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.4	114.0	(36.7-265.9)	Male	6	2.6	228.1	(83.3-496.4)
Female	3	1.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	18	16.7	108.0	(63.9-170.6)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	0	1.9	nc	(nc-nc)

Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	9	6.7	134.1	(61.2-254.5)	Female	2	1.7	nc	(nc-nc)
Female	7	5.6	126.0	(50.5-259.7)	Pancreas				
Esophagus					Male	1	1.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	21	18.6	113.1	(70.0-172.8)
Male	1	0.4	nc	(nc-nc)	Stomach				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	0.6	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Testis				
Female	0	1.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Larynx					Thyroid				
Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	3	1.4	nc	(nc-nc)	Female	5	3.5	144.9	(46.7-338.1)
Female	0	1.0	nc	(nc-nc)	All Sites / Types				
Liver and Intrahepatic Bile Ducts					Male	62	61.2	101.4	(77.7-130.0)
Male	0	1.0	nc	(nc-nc)	Female	50	53.3	93.8	(69.6-123.7)
Female	1	0.3	nc	(nc-nc)					
Lung and Bronchus									
Male	8	8.4	95.0	(40.9-187.2)					
Female	4	7.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

48

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	50	44.3	112.8	(83.7-148.7)	Male	28	23.2	120.9	(80.3-174.7)
Female	15	17.5	85.7	(47.9-141.3)	Female	14	19.7	71.1	(38.9-119.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	7.7	64.9	(20.9-151.4)	Male	2	6.6	nc	(nc-nc)
Female	9	6.9	131.2	(59.9-249.0)	Female	3	5.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	2	1.3	nc	(nc-nc)	Male	19	21.6	87.9	(52.9-137.3)
Female	149	162.1	91.9	(77.8-107.9)	Female	20	21.7	92.1	(56.2-142.2)

Cervix Uteri

Female	9	6.7	133.4	(60.9-253.3)
--------	---	-----	-------	--------------

Colon / Rectum

Male	86	65.4	131.6	(105.2-162.5)
------	----	------	-------	---------------

Female	79	69.2	114.2	(90.4-142.4)
--------	----	------	-------	--------------

Esophagus

Male	10	11.0	90.7	(43.4-166.9)
------	----	------	------	--------------

Female	4	3.4	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	1	2.9	nc	(nc-nc)
------	---	-----	----	---------

Female	5	2.5	197.1	(63.5-459.9)
--------	---	-----	-------	--------------

Kidney & Renal Pelvis

Male	21	17.8	118.1	(73.1-180.5)
------	----	------	-------	--------------

Female	11	12.1	91.1	(45.4-163.0)
--------	----	------	------	--------------

Larynx

Male	5	7.1	70.3	(22.7-164.1)
------	---	-----	------	--------------

Female	1	2.1	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	16	13.4	119.3	(68.1-193.7)
------	----	------	-------	--------------

Female	14	11.9	117.9	(64.4-197.9)
--------	----	------	-------	--------------

Liver and Intrahepatic Bile Ducts

Male	4	8.6	nc	(nc-nc)
------	---	-----	----	---------

Female	2	3.5	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	79	82.3	96.0	(76.0-119.6)
------	----	------	------	--------------

Female	77	81.5	94.5	(74.6-118.1)
--------	----	------	------	--------------

Oral Cavity & Pharynx

Male	18	15.5	116.3	(68.9-183.9)
------	----	------	-------	--------------

Female	6	8.2	73.6	(26.9-160.1)
--------	---	-----	------	--------------

Ovary

Female	17	17.7	96.1	(55.9-153.8)
--------	----	------	------	--------------

Pancreas

Male	15	12.4	121.3	(67.8-200.0)
------	----	------	-------	--------------

Female	12	14.9	80.5	(41.6-140.7)
--------	----	------	------	--------------

Prostate

Male	141	169.7	83.1	(69.9-98.0)
------	-----	-------	------	-------------

Stomach

Male	11	11.2	98.6	(49.1-176.4)
------	----	------	------	--------------

Female	5	7.5	66.8	(21.5-155.9)
--------	---	-----	------	--------------

Testis

Male	4	4.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	5	4.6	109.6	(35.3-255.7)
------	---	-----	-------	--------------

Female	13	15.2	85.6	(45.5-146.4)
--------	----	------	------	--------------

Uteri Corpus and Uterus, NOS

Female	31	34.0	91.3	(62.0-129.6)
--------	----	------	------	--------------

All Sites / Types

Male	565	571.3	98.9	(90.9-107.4)
------	-----	-------	------	--------------

Female	542	568.2	95.4	(87.5-103.8)
--------	-----	-------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

49

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	20.0	85.0	(49.5-136.0)	Male	11	9.3	118.7	(59.2-212.4)
Female	10	6.9	144.5	(69.2-265.7)	Female	13	6.9	188.0	(100.0-321.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	8	2.4	331.3	(142.6-652.8)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	2	0.6	nc	(nc-nc)	Male	10	9.0	111.5	(53.4-205.1)
Female	79	59.0	133.9	(106.0-166.9)	Female	8	8.3	96.9	(41.7-191.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	12	6.0	201.6	(104.1-352.3)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	31	28.6	108.2	(73.5-153.7)	<u>Ovary</u>				
Female	23	27.7	83.1	(52.7-124.7)	Female	7	6.5	107.3	(43.0-221.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.6	108.5	(35.0-253.2)	Male	6	5.4	111.9	(40.9-243.6)
Female	1	1.4	nc	(nc-nc)	Female	7	6.0	117.2	(47.0-241.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	98	69.0	142.0	(115.3-173.0)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.0	100.6	(32.4-234.7)
Male	8	7.1	112.8	(48.5-222.2)	Female	2	3.1	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.8	nc	(nc-nc)
Male	10	5.5	181.0	(86.7-332.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.5	133.4	(48.7-290.4)	Female	14	12.2	114.3	(62.4-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.5	nc	(nc-nc)	Male	286	238.9	119.7	(106.2-134.4)
Female	0	1.4	nc	(nc-nc)	Female	236	213.2	110.7	(97.0-125.8)
<u>Lung and Bronchus</u>									
Male	42	35.7	117.7	(84.8-159.2)					
Female	25	31.2	80.1	(51.8-118.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

50

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	19.5	92.5	(54.8-146.1)	Male	16	13.2	121.4	(69.3-197.2)
Female	5	6.7	75.2	(24.2-175.4)	Female	16	9.9	162.2	(92.6-263.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.9	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)

Female	7	3.4	204.7	(82.0-421.8)	Female	0	2.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	12	11.7	102.9	(53.1-179.8)
Female	89	74.6	119.2	(95.7-146.7)	Female	13	9.0	144.0	(76.6-246.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	8	3.7	217.1	(93.5-427.8)	Male	6	8.9	67.7	(24.7-147.3)
Colon / Rectum					Female	2	3.5	nc	(nc-nc)
Male	33	30.4	108.6	(74.7-152.5)	Ovary				
Female	29	26.1	111.1	(74.4-159.6)	Female	12	8.0	149.9	(77.3-261.8)
Esophagus					Pancreas				
Male	7	5.4	130.6	(52.3-269.0)	Male	7	5.8	121.7	(48.8-250.8)
Female	0	1.3	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	2.5	nc	(nc-nc)	Male	71	81.4	87.2	(68.1-110.0)
Female	1	1.8	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	3	5.1	nc	(nc-nc)
Male	12	9.4	127.2	(65.6-222.2)	Female	0	2.8	nc	(nc-nc)
Female	8	5.2	155.3	(66.9-305.9)	Testis				
Larynx					Male	6	5.0	120.5	(44.0-262.3)
Male	4	3.6	nc	(nc-nc)	Thyroid				
Female	1	0.9	nc	(nc-nc)	Male	5	3.3	150.2	(48.4-350.5)
Leukemia					Female	11	9.2	119.2	(59.4-213.3)
Male	5	7.1	70.4	(22.7-164.2)	Uteri Corpus and Uterus, NOS				
Female	6	5.1	117.1	(42.7-254.8)	Female	13	15.3	85.0	(45.2-145.4)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	2	4.6	nc	(nc-nc)	Male	282	282.4	99.9	(88.5-112.2)
Female	0	1.4	nc	(nc-nc)	Female	270	245.8	109.8	(97.1-123.7)
Lung and Bronchus									

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

51

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	6	3.6	166.8	(60.9-363.2)	Male	1	2.1	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)

Brain and Other Nervous System

Male	1	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Breast

Male	0	0.1	nc	(nc-nc)
Female	12	13.1	91.7	(47.3-160.2)

Cervix Uteri

Female	1	0.6	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	5	5.5	90.8	(29.3-211.9)
Female	4	4.5	nc	(nc-nc)

Esophagus

Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)

Kidney & Renal Pelvis

Male	1	1.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Larynx

Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Leukemia

Male	1	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Lung and Bronchus

Male	9	6.8	132.3	(60.4-251.1)
Female	5	5.5	91.0	(29.3-212.3)

Multiple Myeloma

Male	1	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	0	1.9	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)

Oral Cavity & Pharynx

Male	3	1.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Ovary

Female	0	1.4	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)

Prostate

Male	10	14.7	67.8	(32.5-124.7)
------	----	------	------	--------------

Stomach

Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Testis

Male	1	0.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	1	2.7	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	49	49.6	98.8	(73.1-130.6)
Female	38	42.0	90.4	(64.0-124.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				<u>Melanoma of Skin</u>			

Male	82	85.1	96.4	(76.7-119.6)	Male	44	49.8	88.3	(64.2-118.6)
Female	27	33.0	81.9	(54.0-119.2)	Female	43	44.6	96.5	(69.8-130.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	18.3	98.4	(58.3-155.6)	Male	15	13.0	115.2	(64.4-190.0)
Female	17	15.7	108.2	(63.0-173.2)	Female	8	10.4	76.9	(33.1-151.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.6	nc	(nc-nc)	Male	34	45.5	74.6	(51.7-104.3)
Female	294	342.4	85.9	(76.3-96.3)	Female	40	43.4	92.3	(65.9-125.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	26	16.2	160.0	(104.5-234.5)	Male	40	33.3	120.2	(85.9-163.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	136	128.2	106.0	(89.0-125.4)	Female	44	37.1	118.7	(86.3-159.4)
Female	145	130.4	111.2	(93.8-130.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	27	24.3	111.2	(73.3-161.8)
Male	35	22.0	159.1	(110.8-221.3)	Female	32	27.8	115.2	(78.8-162.6)
Female	9	6.4	141.0	(64.3-267.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	274	337.4	81.2	(71.9-91.4)
Male	5	8.2	61.3	(19.7-143.0)	<u>Stomach</u>				
Female	3	7.3	nc	(nc-nc)	Male	32	21.8	146.6	(100.3-207.0)
<u>Kidney & Renal Pelvis</u>					Female	17	14.0	121.1	(70.5-194.0)
Male	33	37.0	89.2	(61.4-125.3)	<u>Testis</u>				
Female	22	24.4	90.3	(56.6-136.8)	Male	10	14.5	69.1	(33.1-127.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	15	14.4	104.3	(58.4-172.1)	Male	12	11.1	107.8	(55.6-188.3)
Female	5	4.2	117.8	(38.0-274.8)	Female	52	39.4	132.0	(98.6-173.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	33	28.9	114.2	(78.6-160.4)	Female	66	70.8	93.2	(72.0-118.5)
Female	21	24.7	84.9	(52.6-129.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1163	1154.3	100.8	(95.0-106.7)
Male	25	17.9	139.8	(90.5-206.4)	Female	1171	1159.2	101.0	(95.3-107.0)
Female	4	6.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	196	159.4	123.0	(106.3-141.4)					
Female	172	155.9	110.3	(94.5-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	17	12.8	132.3	(77.0-211.9)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	5.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	6	4.7	128.5	(46.9-279.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	11	13.9	79.4	(39.6-142.1)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	1	0.6	nc	(nc-nc)	Male	43	47.2	91.2	(66.0-122.8)
Female	0	0.2	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	0	1.1	nc	(nc-nc)	Female	54	42.5	127.0	(95.4-165.8)
Female	2	0.9	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	1	0.7	nc	(nc-nc)	Male	8	6.7	119.9	(51.6-236.3)
Female	0	0.2	nc	(nc-nc)	Female	15	6.0	251.9	(140.9-415.5)
<u>Lung and Bronchus</u>					<u>Female</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	53.1	88.6	(65.1-117.8)	Male	44	30.8	142.9	(103.9-191.9)
Female	23	22.1	104.2	(66.0-156.3)	Female	47	30.1	156.3	(114.8-207.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	10.5	114.3	(59.0-199.7)	Male	5	8.1	61.8	(19.9-144.2)
Female	8	9.9	81.1	(34.9-159.8)	Female	5	7.0	71.8	(23.1-167.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	41	28.0	146.2	(104.9-198.4)
Female	269	222.3	121.0	(107.0-136.4)	Female	38	28.9	131.5	(93.1-180.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	10.8	65.1	(26.1-134.1)	Male	14	20.3	69.0	(37.7-115.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	79.7	81.5	(62.9-103.9)	Female	27	24.3	111.0	(73.1-161.5)
Female	74	89.5	82.7	(64.9-103.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	15.0	93.0	(50.8-156.1)
Male	9	13.5	66.5	(30.4-126.3)	Female	19	18.9	100.7	(60.6-157.3)
Female	3	4.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	218	205.8	105.9	(92.3-120.9)
Male	6	5.1	117.2	(42.8-255.2)	<u>Stomach</u>				
Female	6	5.0	118.8	(43.4-258.7)	Male	9	13.6	66.0	(30.1-125.2)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	28	22.4	125.2	(83.2-181.0)	Female	11	9.8	111.8	(55.7-200.0)
Female	17	15.8	107.9	(62.8-172.8)	<u>Thyroid</u>				
<u>Larynx</u>					Male	15	9.5	157.3	(88.0-259.4)
Male	4	8.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.7	nc	(nc-nc)	Female	58	45.8	126.6	(96.1-163.6)
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	24	17.2	139.7	(89.5-207.9)	Male	696	709.3	98.1	(91.0-105.7)
Female	20	16.1	124.4	(76.0-192.2)	Female	841	765.8	109.8	(102.5-117.5)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	10	10.9	91.7	(43.9-168.6)					
Female	4	4.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	65	97.9	66.4	(51.2-84.6)					
Female	86	101.1	85.1	(68.1-105.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	10	8.3	120.1	(57.5-220.9)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	9.3	53.8	(17.3-125.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	24	31.2	76.9	(49.3-114.4)
Male	0	0.5	nc	(nc-nc)	Female	27	27.2	99.4	(65.5-144.7)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	4.4	nc	(nc-nc)					
Female	5	3.6	137.4	(44.3-320.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

56

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	25.3	114.8	(76.8-164.8)	Male	20	14.6	136.7	(83.5-211.2)
Female	4	8.9	nc	(nc-nc)	Female	10	11.7	85.4	(40.9-157.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.1	138.5	(55.5-285.3)	Male	3	3.9	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	13.1	121.9	(69.6-198.0)
Female	103	95.7	107.6	(87.8-130.5)	Female	13	11.5	113.3	(60.3-193.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.3	164.2	(65.8-338.3)	Male	7	10.2	68.9	(27.6-142.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	38.3	78.4	(52.9-111.9)	Female	4	10.2	nc	(nc-nc)
Female	38	33.5	113.4	(80.3-155.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	7	6.8	103.2	(41.3-212.5)	Male	116	110.0	105.5	(87.2-126.5)
Female	4	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	2.0	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	11.3	70.5	(30.4-139.0)	Female	18	20.6	87.2	(51.7-137.8)
Female	5	6.7	74.2	(23.9-173.2)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	6	4.5	133.2	(48.6-289.9)	Male	9	8.1	111.2	(50.7-211.1)
Female	0	1.3	nc	(nc-nc)	Female	10	6.2	162.3	(77.7-298.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	5.5	nc	(nc-nc)	Male	45	49.3	91.3	(66.6-122.2)
Female	0	1.8	nc	(nc-nc)	Female	48	44.4	108.2	(79.8-143.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

57

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	73.6	77.5	(58.7-100.4)	Male	46	46.7	98.5	(72.1-131.4)
Female	26	29.4	88.3	(57.7-129.4)	Female	39	45.0	86.6	(61.6-118.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	16.9	59.2	(28.3-108.8)	Male	7	11.3	61.7	(24.7-127.1)
Female	10	14.6	68.5	(32.8-126.1)	Female	9	9.3	96.4	(44.0-183.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.2	nc	(nc-nc)	Male	32	42.2	75.9	(51.9-107.1)
Female	308	315.4	97.6	(87.0-109.2)	Female	40	40.2	99.6	(71.2-135.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	16.5	48.6	(20.9-95.7)	Male	28	29.4	95.1	(63.2-137.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	109	111.8	97.5	(80.0-117.6)	Female	44	34.5	127.6	(92.7-171.3)
Female	91	116.8	77.9	(62.7-95.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	21.0	100.0	(61.9-152.9)
Male	11	19.1	57.7	(28.8-103.2)	Female	26	24.8	105.0	(68.6-153.9)
Female	7	5.7	122.8	(49.2-253.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	305	289.1	105.5	(94.0-118.0)
Male	9	10.7	84.4	(38.5-160.3)	<u>Stomach</u>				
Female	3	9.0	nc	(nc-nc)	Male	21	19.2	109.5	(67.8-167.5)
<u>Kidney & Renal Pelvis</u>					Female	19	12.6	151.1	(90.9-235.9)
Male	25	32.3	77.3	(50.0-114.1)	<u>Testis</u>				
Female	20	22.1	90.5	(55.3-139.8)	Male	17	20.9	81.2	(47.3-130.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	12.4	104.6	(55.7-178.9)	Male	13	11.5	113.5	(60.4-194.0)
Female	4	3.8	nc	(nc-nc)	Female	34	42.6	79.8	(55.3-111.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	26.2	80.2	(49.6-122.5)	Female	75	65.0	115.3	(90.7-144.5)
Female	20	22.3	89.8	(54.9-138.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	926	1023.6	90.5	(84.7-96.5)
Male	18	15.7	114.6	(67.9-181.1)	Female	988	1070.9	92.3	(86.6-98.2)
Female	12	6.1	196.5	(101.4-343.3)					
<u>Lung and Bronchus</u>									
Male	106	137.7	77.0	(63.0-93.1)					
Female	109	139.8	77.9	(64.0-94.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

58

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	26.2	95.4	(61.7-140.8)	Male	14	14.0	99.7	(54.5-167.3)
Female	13	10.5	124.4	(66.2-212.7)	Female	8	12.0	66.9	(28.8-131.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.7	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	9	13.0	69.2	(31.6-131.3)
Female	89	97.1	91.7	(73.6-112.8)	Female	10	13.0	76.7	(36.7-141.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.2	nc	(nc-nc)	Male	6	9.4	63.7	(23.3-138.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	38.8	116.0	(84.6-155.2)	Female	5	10.6	47.1	(15.2-109.8)
Female	48	42.2	113.7	(83.8-150.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	7.3	150.1	(74.8-268.5)
Male	8	6.5	122.7	(52.9-241.9)	Female	12	9.0	133.6	(69.0-233.4)
Female	2	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	105	99.6	105.4	(86.2-127.6)
Male	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.6	nc	(nc-nc)	Male	6	6.6	90.3	(33.0-196.5)
<u>Kidney & Renal Pelvis</u>					Female	3	4.7	nc	(nc-nc)
Male	12	10.6	113.0	(58.3-197.5)	<u>Testis</u>				
Female	6	7.2	83.8	(30.6-182.4)	Male	1	2.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.2	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	18	9.4	191.3	(113.3-302.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.0	99.5	(42.9-196.2)	Female	17	20.0	85.0	(49.5-136.1)
Female	7	7.3	96.3	(38.6-198.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	334	338.8	98.6	(88.3-109.8)
Male	5	5.2	97.0	(31.2-226.3)					
Female	4	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	48.1	91.6	(66.5-122.9)					

Female 51 47.4 107.5 (80.1-141.4)

Female 332 340.9 97.4 (87.2-108.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;